Tatiana Novobrantseva

Tatiana Novobrantseva

Company: Verseau Therapeutics

Job title: Co-founder & Chief Scientific Officer


Tatiana Novobrantseva is a Co-Founder and CSO of Verseau. Before Verseau, she consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer. Previously, Tatiana served as Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Tatiana’s accomplishments span multiple therapeutic areas in programs from discovery to development.


Completing the Immunity Cycle by Developing Macrophage Immunotherapies 2:00 pm

• Assess how macrophages and dendritic cells are biologically optimized to either induce or suppress an immune response • Understand why repolarizing pro-tumorigenic macrophages has been repeatedly identified as a crucial next step for the field of immuno-oncology • Outline how myeloid cell suppression has been fuelling the vicious cycle of the autoimmune disease •…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.